0:05 You are listening to the global network of podcasters dedicated to the pharmacy profession. 0:10 Welcome to the Pharmacy Podcast Network. 0:27 In this episode of Outcomes, Insights Beyond the Counter... Host John Grice and his guest Mark Olberding are discussing the Medicare Request for Information, or RFI, to highlight why it matters and give pharmacies key topics to cover to provide meaningful, data-driven feedback. 0:43 All right. Hey, everybody. 0:44 Welcome back to another episode of Outcomes Insights Beyond the Counter. 0:48 I'm your host, John Grice, and I'm joined today by Mark Olberding. 0:51 Mark is a longtime expert in pharmacy, pharmacy data analysis. Claims, understanding the intelligence behind pharmacy, how it operates. And today we've got an interesting topic. Talking about the Medicare RFI. 1:05 RFI stands for a request for information that CMS has put out. where they want to know some data, and they want to understand a little bit better from the pharmacy directly what's going on in your business, how certain numbers, metrics, 1:19 contracts are working, all so that they can take that back, understand a little bit better the picture that every pharmacy is facing day in, day out, and start to make some changes. If you've seen it already, hopefully this will 1:35 give you a little more direction or help clarify some things. 1:38 If you haven't heard of this yet, please Google Medicare RFI. 1:42 Take a look at our website. We've got a blog post out that talks about it. Or NCPA is another great resource where we're all trying to talk to pharmacy, pharmacy owners, independents, and say, this matters. This is a key time, an opportunity for you to share how your 2:00 business is operating and with someone who is interested, who is going to be looking at how to make pharmacy healthy and work better for all the patients that you guys are all serving. So, Mark, you know, to dive right into it, you've been looking at pharmacy and the 2:17 business behind it for a long time. Tell me a little bit about how your career and the evolution of what you've seen in pharmacy, how it's changed and how Maybe through that, tell me about some opportunities where we've had in the past to share claim-level data in the 2:37 hopes of seeing change happen. 2:38 Yeah, absolutely. 2:40 And thanks for having me, John. I don't know about expert, but I do appreciate that. So, Mark Oberdeen, I'm a pharmacist by background. Spent a lot of my early career working in an independent pharmacy just south of Kansas City. 2:58 a lot of time behind the bench, while at the same time working with an individual, shout out to Monty Rogers, kind of gave me a chance to get into the business side of things. He had extensive business and PSAOs 3:13 and managed care and helping pharmacies make sure they're financially a well-running engine. 3:19 And so I was able to pick. 3:21 Up a wealth of information from him and through the years have been able to combine that experience with my work, you know, actually in an independent pharmacy, in a retail pharmacy, and, you know, have hopefully helped a few stores over the years. 3:39 I think what's pertinent for this topic specifically, and what excites me the most, John, when you pointed this out, is usually in the past when we've been asked to provide information. 3:54 It's sort of been in a catastrophic form. 3:58 I remember managing a PSAO, and at one point, we were having to promote our stores just to stay in the network. 4:07 And so I think it's very exciting that we have. 4:11 An opportunity to get in front of Medicare and kind of show them some of the issues we've been experiencing. 4:18 To your point, the changes that I've seen over the years have been crazy. I started 2010 is when I graduated pharmacy school. We hadn't really hit the profitability cliff. 4:31 It's been a struggle since then and obviously has gotten worse over the years with the extended day supply, mail order rates, then we get to DIR fees and network rebate fees and things like that. So tremendous opportunity here, I think, for us. 4:49 Cool. I agree with you. 4:51 I think looking over it at first, it looked daunting. 4:53 It's a big, long document, lots of detail in it. 4:57 But as I sat back and thought about it, I thought this is a great opportunity, like you said. And it's at a key time. Both of us are sitting here going, we can refer to the DIR days as an era that we lived through and now we're looking 5:13 back on. And so I think to have CMS recognizing, all right, we're outside of that whole structure. 5:21 And if there's a new. 5:22 Dynamic to the market that's out there, they want to learn about it. They want to know what's going on. 5:28 They make large policy and then let it get enacted. 5:33 And now they want to, I think, hear from the pharmacies directly. So how's it going? And I mean, just in the last couple of years, they've had a couple of programs roll out, you know, the MFP and how that has changed some things and is going to continue expanding. 5:48 And I think this is just a really good opportunity for each pharmacy to sort of raise their hand and say, yeah, here's how my business is doing. Because I know, I know that sometimes our efforts almost sound doom and gloomy. 6:03 And if that's all they hear, maybe they actually not tune it out, but it doesn't quite land the same if it's the same message over and over. So yeah, I looked at it the same way, an opportunity like we've seen before. Let's Let's talk about the actual RFI 6:21 a little bit. There's five main sections in it, but there's really kind of just one that's focused on claims data. 6:31 How have you seen value in looking at just a lot of claims and trying to pick out the key points? 6:39 They've got a good list, some specifics. 6:42 We want to see how many claims are getting paid under cost and things like that. But were there any particular key points that you thought a pharmacy should maybe focus on specifically? that's going to drive the story the best, right? 6:56 We've got a story and we know that just repeating the broad arching isn't going to get us there. What data points do you think are going to be the most meaningful for pharmacies to be looking for? 7:08 Yeah, absolutely. 7:09 And to your point on doing a lot of work, doom and gloom, and I remember submitting thousands of MAC appeals a month through the PSAO, rarely getting a response, but at least ensuring we did get a response and making them say, hey, we know we're reimbursing you under 7:32 a cost. I think it's important to continue you know, those detailed efforts. You know, it's not top of mind every day like it is for us and all of our pharmacies out there. So for this specifically, you know, I think it's going to be important to be detailed, accurate, 7:57 and really succinct where you can be. I mean, we want to provide a lot of information, but it's a person on the other end who has to digest it and make sense of it. So of course you want to hit things like your cost, your reimbursement. In those, 8:17 be sure to include the ingredient cost discount and the dispensing fee. I know that that is something specifically that they're trying to determine how that should apply. I understand there's very few dispensing fees out there nowadays anyway, but 8:32 important to give them the whole picture, an accurate cost, an accurate reimbursement, But then I think also being able to articulate that that's just your break-even point on the product itself. I think you pointed out, John, in your 8:50 blog that it's also important to let them know that that's not the true cost to dispense a drug. We haven't taken into account salaries. We haven't taken into account rent. 8:58 We haven't taken into account things like that. And so I think that's important to point out and you know, calculate in your data if you can, but not to the point that it takes away from what they're trying to solve, which is the actual drug reimbursement. So I 9:16 think being clear and concise will be extremely important here. 9:22 I think you're right. 9:23 I think the volume is another key piece to say, all right, any one store's data is not going to be the data point that gets it done, but everybody working together, everybody submitting these is how we're actually going. 9:37 To prove success. 9:39 A story, and then we can expect to see some change come out of that. So yeah, all those details will be relevant. Trying to run reports out of your PMS is just going to tell you that drug story, and that's a good one. All of the pharmacies that can, should, 9:57 and as many other folks who are able to get at that other data, like you mentioned, all the overhead costs, all of the other things that go into the cost of running a pharmacy, please grab that as well. Because the more data, the more people that can be submitting information, 10:12 the bigger the story. 10:13 I know there's a. 10:16 There's sometimes a feeling I get when I'm being asked to give an opinion in a sea of other opinions where you're like, well, does it even matter? 10:24 Well, it does. It does. It doesn't feel like it. 10:28 But at the same time, if every voice in that big sea was also to feel the same way and not do anything with it, then nothing would get done. 10:40 And so this is an opportunity where it's not just a rah-rah situation. Give it a good try. 10:46 It's, hey, we do. 10:48 We need everybody to speak up, share your story. And so the more data points you can, the better. We've worked a little bit. When I first came aboard, you and I worked through writing up a blog about some pharmacy details, claims detail, metrics like that. So here we 11:05 are again talking a similar story. Our PMS system has some reports. I think every PMS out there has some canned reports that will address most of the pieces that are in this. Our blog focuses on our tools. I get that we wrote it to a narrow group of folks, 11:24 but every PMS is able to pull claims data paid under cost, the figures you were talking about. How about the other contracts? How much of that Do you think it's worth going to all of the Part D contracts that are out there and trying to grab maybe averages 11:45 or the best and the worst. 11:48 Contracts? 11:50 What resources would you point people to there if it's not data that's in their PMS? 11:55 Yeah, you know, I think. 11:57 I think that the PMS will tell the facts of the reimbursement situation. I do think that there are– I don't know the opportunity to share confidential information of your PBM contracts. So be careful there, but there are a 12:17 lot of other really pertinent business terms that Things like your payment cycle, your payment schedule, is the PBM being compliant with any prompt pay laws, your audit sections. 12:32 Wherever you have. 12:37 Personally been, um, you know, experienced an issue in the past that you would like to be addressed. 12:43 I think, I think now is the time. Um, I also think now is, it's a. 12:48 Good time to consult with your PSAO to see if they have any, maybe they're participating this on your behalf in some, some fashion as well, but I think that's a good resource obviously for your contracts and what you, what you can and cannot share. 13:03 Um, but yes, very important to, to, uh. 13:08 De-identify, keep confidential certain terms because those are not meant for widespread distribution and your PBMs obviously would not appreciate that. 13:21 That's a great point. Yeah. 13:23 But again, you were talking earlier, John, about your opinion just being one in a sea of opinions, but I do agree. If no one speaks up, then they're going to move on to something else. And The other thing that's frustrating or could be frustrating as you read, you know, 13:42 this RFI is that I think this is for the planned year of 2029. And so I would just say don't get disheartened by that. I'm still planning to be here in 2029. I know you are, John, and I'm sure all of our pharmacies are as well. And so, 13:57 you know, it's just going to take time to get, you. 14:02 Know, answers on some of this stuff. 14:04 But, you know, we really need to to, to show them the issues that we're experiencing. And I, you know, I keep going back to Mac appeals and, you know, whenever you're sending the same drug, the same NDC over and over and over, eventually somebody does get, they realize, 14:20 and they, they don't want to get that Mac appeal anymore, you know? And I think that, you know, if we keep, keep on them, hopefully we can get some, some positive change, but it is, it's encouraging the, the attention that we're receiving right now. 14:35 That's true. 14:36 And you're right. 14:37 I think another way to say what you just said is it might be an endurance game, and we've just got to be willing to stay dug in for that, have the long-term perspective, and be willing to keep saddling up with the effort of, yep, the endurance of continuing 14:53 to share, continuing to work towards that better is the only way you end up getting there. And yeah, it may not be till 2029, but that's great that we started now and not next year or the year after. 15:07 You mentioned PSAOs. I know earlier we mentioned NCPA. There's groups out there that can help. There's groups out there that have interest. Our friends at NCPA are developing some tools right now. They've got a survey that's out to a small number. 15:25 Of their advisory board that I've heard about that's. 15:28 Submitting some responses through that method. They've got a draft template of a response of how you can take the data, like what you might find using our blog post, but put it into NCPA's template to be able to kind of make this a little bit easier. If there's other resources, 15:49 any you know of, Mark, I think I was just going to kind of wrap that thought up with any more, and we'll put it out after this. But we are getting short on time. 15:59 Yeah, I would say that it definitely used the NCPA template. 16:03 We would create templates for our pharmacies because it's not something you do every day. But I am very confident that NCPA has their template in a format that's going to be understandable to the federal government. So absolutely utilize 16:20 those tools and help NCPA help us. You know, they do a great job. They're out there every day in the trenches and, you know, whatever information we can arm them with will be well worth it in the long run. 16:34 Yeah, exactly. I'm hopeful. 16:36 I really think that if we can have some say as pharmacists, the overall that we're all driving towards is how to build contracts in a way that enables pharmacies to keep taking the best care of their patients, right? 16:49 Nobody's trying to win over somebody else in the whole game here. It's all about how do we make sure the patients have access and a healthy, successful running pharmacy. 16:59 And so this is a key piece to how we get that accomplished. So yeah, the deadline coming up on November 23rd is already right around the corner. And if you haven't gotten a chance to take a look at this yet, dig in, take a peek. If you need help, 17:17 reach out, either here at Outcomes, we'd love to help you, or NCPA, like we've mentioned, or your PSAO for some of those contract questions like Mark mentioned. And I'd love to see maybe more of a conversation after this, uh, maybe below in the comment section or engage with us 17:35 on social media. Um, and we can get more of a conversation going here, but, uh, Mark, any last thoughts, um, any, any closing ideas for how to make, uh, that contract that we just, uh, kind of talked around? Um, what's that look like or how would you see the future, uh, 17:53 contract working best? 17:56 Yeah, I don't think so. 17:57 I mean, I think it's just a matter of doing the work, submitting exactly what they're asking for. Don't overwhelm them. 18:08 Stay calm as you're submitting these. Getting riled up, getting angry isn't going to help the situation with them, but present them with the facts in a clear, concise manner. And, um, you know, don't, don't get discouraged is the biggest thing 18:25 we have to, you know, we've made it this far. Um, and, you know, we just got to keep, keep fighting the good fight. But I, you know, I think, I think that's probably all I would say, John. 18:38 You got it. Well, yeah. Stay calm and submit your responses. 18:43 You know, that's a good closing thought for that one. 18:46 So, all right. Well, thank you. Thanks, Mark, for joining me. 18:49 Thank you all for listening in. 18:51 And thanks for joining us for another episode of Insights Beyond the Counter. 18:56 Take care. 18:57 Thanks, John.
Community discussion